Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitozantrone versus CMFP in advanced breast cancer
ACTRN12607000095460Phase 3Completed
- Sponsor
- Breast Cancer Trials
- Start
- Jan 1988
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitoxantrone, cyclophosphamide, methotrexate, fluorouracil and prednisone in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoints: Time to disease progression, Overall survival and 3 more. Started Jan 1988; status: completed.
02
Drugs
mitoxantronecyclophosphamidemethotrexatefluorouracilprednisone
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000095460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000095460.